EQUITY RESEARCH MEMO

Phenox

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)50/100

Phenox, a German medical device company founded in 2005 and headquartered in Bochum, specializes in neurovascular interventions. Its portfolio includes mechanical thrombectomy devices for ischemic stroke and flow diverters/implants for complex intracranial aneurysms. The company is dedicated to providing clinically proven, innovative solutions that improve patient outcomes. With a focus on disruptive technologies, Phenox has established itself as a key player in the neurovascular space, serving a critical need in minimally invasive treatments. Despite being private with limited public financial data, the company's long-standing presence and specialized product line suggest a stable operational base. However, the absence of disclosed upcoming milestones or pipeline details tempers near-term conviction.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)